siRNA targeting myeloid cell leukemia sequence 1
View Patent ↗Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
1. An siRNA molecule consisting of: (a) a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region consisting of 19-30 base pairs and said antisense region comprises a sequence that is the complement of SEQ ID NO 461; and (b) either zero overhang regions, or one or more overhang regions, wherein each overhang region is six or fewer nucleotides in length.
2. The siRNA molecule of claim 1 , wherein said antisense region and said sense region are each 19-25 nucleotides in length.
3. The siRNA molecule of claim 2 , wherein said antisense region and said sense region are each 19 nucleotides in length.
4. The siRNA molecule of claim 1 , wherein said antisense region is 100% complementary to a region of a target mRNA.
5. The siRNA molecule of claim 1 , wherein said siRNA molecule has at least one overhang region.
6. The siRNA molecule of claim 1 , wherein said siRNA molecule has only one overhang region.
7. The siRNA molecule of claim 1 , wherein said siRNA molecule has two overhang regions.
8. The siRNA molecule of claim 1 , wherein said siRNA molecule has no overhang regions.
9. The siRNA molecule of claim 2 , wherein said siRNA molecule has at least one overhang region.
10. The siRNA molecule of claim 2 , wherein said siRNA molecule has no overhang regions.
11. The siRNA molecule of claim 3 , wherein said siRNA molecule has at least one overhang region.
12. The siRNA molecule of claim 3 , wherein said siRNA molecule has no overhang regions.
13. A chemically synthesized double stranded siRNA molecule that directs cleavage of an mRNA via RNA interference, wherein:
a. each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length; and
b. one strand of said double stranded siRNA molecule comprises a sequence that is the complement of SEQ ID NO 461.
14. The chemically synthesized double stranded siRNA molecule of claim 13 , wherein each strand of said double stranded siRNA molecule is 19 nucleotides in length.
15. An siRNA molecule, wherein said siRNA molecule consists of: (a) a sense region, wherein said sense region consists of a sequence that is SEQ ID NO 461, and an antisense region, wherein said antisense region consists of a sequence that is the complement of SEQ ID NO 461; and (b) either zero overhang regions, or one or more overhang regions, wherein each overhang region is six or fewer nucleotides in length.
16. The siRNA molecule of claim 15 , wherein said siRNA molecule has no overhang regions.
17. The siRNA molecule of claim 16 , wherein said siRNA molecule has one overhang region.
18. The siRNA molecule of claim 17 , wherein said siRNA molecule has two overhang regions.